BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25648497)

  • 21. The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation.
    Garcia-Fernandez MO; Schally AV; Varga JL; Groot K; Busto R
    Breast Cancer Res Treat; 2003 Jan; 77(1):15-26. PubMed ID: 12602901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1-STAT3/NF-κB signaling.
    Gan J; Ke X; Jiang J; Dong H; Yao Z; Lin Y; Lin W; Wu X; Yan S; Zhuang Y; Chu WK; Cai R; Zhang X; Cheung HS; Block NL; Pang CP; Schally AV; Zhang H
    Proc Natl Acad Sci U S A; 2016 Dec; 113(51):14745-14750. PubMed ID: 27930339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer.
    Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Sánchez-Chapado M; Prieto JC; Bajo AM
    Oncotarget; 2016 Aug; 7(32):52195-52206. PubMed ID: 27448980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities.
    Zarandi M; Varga JL; Schally AV; Horvath JE; Toller GL; Kovacs M; Letsch M; Groot K; Armatis P; Halmos G
    Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4610-5. PubMed ID: 16537407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
    Seitz S; Hohla F; Schally AV; Moder A; Engel JB; Horn F; Varga J; Zarandi M; Ortmann O; Köster F; Buchholz S
    Oncol Rep; 2008 Nov; 20(5):1289-94. PubMed ID: 18949435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells.
    Vacas E; Muñoz-Moreno L; Valenzuela PL; Prieto JC; Schally AV; Carmena MJ; Bajo AM
    Peptides; 2016 Dec; 86():153-161. PubMed ID: 27816751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
    Stangelberger A; Schally AV; Rick FG; Varga JL; Baker B; Zarandi M; Halmos G
    Prostate; 2012 Apr; 72(5):555-65. PubMed ID: 21796649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endocrine and antineoplastic actions of growth hormone-releasing hormone antagonists.
    Kovács M; Schally AV; Varga JL; Zarándi M
    Curr Med Chem; 2008; 15(4):314-21. PubMed ID: 18288987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J; Emons G; Pinski J; Schally AV
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormone.
    Jimenez JJ; DelCanto GM; Popovics P; Perez A; Vila Granda A; Vidaurre I; Cai RZ; Rick FG; Swords RT; Schally AV
    Br J Haematol; 2018 May; 181(4):476-485. PubMed ID: 29663325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
    Klukovits A; Schally AV; Szalontay L; Vidaurre I; Papadia A; Zarandi M; Varga JL; Block NL; Halmos G
    Cancer; 2012 Feb; 118(3):670-80. PubMed ID: 21751186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
    Plonowski A; Schally AV; Varga JL; Rekasi Z; Hebert F; Halmos G; Groot K
    Prostate; 2000 Jul; 44(2):172-80. PubMed ID: 10881027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
    Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
    Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
    Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
    Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.
    Letsch M; Schally AV; Busto R; Bajo AM; Varga JL
    Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1250-5. PubMed ID: 12538852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonists.
    Jaszberenyi M; Rick FG; Popovics P; Block NL; Zarandi M; Cai RZ; Vidaurre I; Szalontay L; Jayakumar AR; Schally AV
    Proc Natl Acad Sci U S A; 2014 Jan; 111(2):781-6. PubMed ID: 24379381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling.
    Kanashiro CA; Schally AV; Zarandi M; Hammann BD; Varga JL
    Int J Cancer; 2004 Nov; 112(4):570-6. PubMed ID: 15382037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
    Rekasi Z; Varga JL; Schally AV; Halmos G; Armatis P; Groot K; Czompoly T
    Endocrinology; 2000 Jun; 141(6):2120-8. PubMed ID: 10830299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ghrelin and obestatin modulate growth hormone-releasing hormone release and synaptic inputs onto growth hormone-releasing hormone neurons.
    Feng DD; Yang SK; Loudes C; Simon A; Al-Sarraf T; Culler M; Alvear-Perez R; Llorens-Cortes C; Chen C; Epelbaum J; Gardette R
    Eur J Neurosci; 2011 Sep; 34(5):732-44. PubMed ID: 21777303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors.
    Cunha SR; Mayo KE
    Endocrinology; 2002 Dec; 143(12):4570-82. PubMed ID: 12446584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.